Webb11 apr. 2024 · El consejo de administración de Shanghai Junshi Biosciences Co, Ltd. ha anunciado que recientemente se ha iniciado un estudio clínico de fase III, aleatorizado, … WebbFör 1 dag sedan · Shanghai Junshi Biosciences Co., Ltd. Announces Vv116 Versus Paxlovid for Early Treatment of Mild to Moderate Covid-19 Reaches Primary Endpoint in …
Home - 君实生物
Webb3 apr. 2024 · Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People’s Republic of China. Webb16 dec. 2024 · Shanghai JunTop Biosciences Co., Ltd.* (hereinafter referred to as “JunTop Biosciences”), a wholly-owned subsidiary of Shanghai Junshi Biosciences Co., Ltd.* (hereinafter referred to as the “Company”), proposes to increase its registered capital by RMB140,366,972, and 14 investors including Gongqingcheng Ruiji Phase VI grass trimmers b and q
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科 …
Webb2 jan. 2024 · Il consiglio di amministrazione di Shanghai Junshi Biosciences Co. Ltd. ha annunciato che lo studio clinico di fase III della compressa VV116 , un farmaco orale analogo del nucleoside anti-SARS-CoV-2... 4 gennaio 2024 WebbCompany Information. Principal Place of Business in Hong Kong Level 54, Hopewell Centre 183 Queen’s Road East Hong Kong. Stock Code 1877. ... SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE ADDITION OF A NEW IMPLEMENTATION ENTITY FOR INVESTMENT PROJECTS. Investor Relations Corporate Information Announcements Webb3 dec. 2024 · Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE DRUG DEVELOPMENT AND LICENSE CONTRACT WITH HANGZHOU DAC MarketScreener Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make … chloe kealey brown rudnick